Inclusion Criteria:  Conforms to the diagnosis criteria for metabolic syndrome (based on the MetS diagnostic criteria developed by IDF and AHA in 2009), that is, having three or more of the following traits:  waist circumference ≥90 cm in men or ≥80 cm in women; Triglyceride level of 150 mg/dL (1.7mmol/L) or higher; High-density lipoprotein (HDL) cholesterol level less than 40 mg/dL (men) or 50 mg/dL (women); Blood sugar over 100 mg/dL (5.6mmol/L), or diagnosed as T2DM and received oral hypoglycemic drugs; Blood pressure over 130/85 mmHg, or diagnosed as hypertension and received medication. Be over 18 years old or younger than 65 years old, no gender limit. Have a good follow-up compliance and can be followed up for more than 3 months; From 2 weeks before enrollment to the end of the entire trial, the drug use will not change; From 2 weeks before enrollment to the end of the entire trial, insulin, drugs and food that affect gastrointestinal absorption, such as Baitangping, were not used.  Exclusion Criteria:  Pregnant and lactating women; Allergic or toxic reactions to gynostemma and other drugs; Infectious diseases such as viral hepatitis, AIDS, syphilis, tuberculosis are active; After drug treatment, still showing high blood sugar (fasting blood glucose higher than 200mg/dL, 11.1mmol/L) or hyperlipidemia, or hypertension (higher than 180/100 mmHg); Any conditions judged by the investigator that affect enrollment.